-
51.发明申请公开(公告)号：US20110136737A1
公开(公告)日：2011-06-09
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/22 , C07K14/645 , C07K14/605 , A61K38/26 , A61P3/10 , A61P9/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
52.发明授权Amylin agonist for treating depression, anxiety disorder and schizophrenia 失效用于治疗抑郁症，焦虑障碍和精神分裂症的胰岛淀粉样多肽激动剂公开(公告)号：US07671023B2
公开(公告)日：2010-03-02
申请号：US11910206
申请日：2006-03-31
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
公开(公告)号：US07608692B2
公开(公告)日：2009-10-27
申请号：US12101689
申请日：2008-04-11
CPC分类号： C07K14/605 , A61K47/60
摘要： Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
摘要翻译： 提供了具有与一种或多种聚乙二醇聚合物连接的毒蜥外泌肽或毒蜥外泌激素的修饰的毒蜥外泌肽和毒蜥外泌肽激动剂，以及相关的制剂和剂量以及施用方法。 这些修饰的毒蜥外泌肽和毒蜥外泌肽激动剂，组合物和方法可用于治疗通过降低血浆葡萄糖或延迟和/或减缓胃排空或抑制食物摄取而受益的糖尿病和病症。
-
公开(公告)号：US20090054341A1
公开(公告)日：2009-02-26
申请号：US12247141
申请日：2008-10-07
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US07442680B2
公开(公告)日：2008-10-28
申请号：US10656093
申请日：2003-09-05
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要： Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译： 公开了增加尿流量的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症，例如肾衰竭，充血性心力衰竭，肾病综合征，肝硬化，肺水肿和高血压。 本发明还涉及诱导肌力反应的方法，包括施用有效量的GLP-1，毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号：US20080176802A1
公开(公告)日：2008-07-24
申请号：US12046038
申请日：2008-03-11
CPC分类号： C07K14/605 , A61K47/60
摘要： Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
摘要翻译： 提供了具有与一种或多种聚乙二醇聚合物连接的毒蜥外泌肽或毒蜥外泌激素的新型修饰的毒蜥外泌肽和毒蜥外泌肽激动剂，以及相关的制剂和剂量以及施用方法。 这些修饰的毒蜥外泌肽和毒蜥外泌肽激动剂，组合物和方法可用于治疗通过降低血浆葡萄糖或延迟和/或减缓胃排空或抑制食物摄取而受益的糖尿病和病症。
-
57.发明授权Methods and compositions for treating pain with amylin or agonists thereof 失效用胰岛淀粉样多肽或其激动剂治疗疼痛的方法和组合物
公开(公告)号：US5677279A
公开(公告)日：1997-10-14
申请号：US767169
申请日：1996-12-16
申请人： Andrew A. Young
发明人： Andrew A. Young
IPC分类号： A61K38/22
CPC分类号： A61K38/22 , A61K31/439 , A61K31/485 , A61K45/06
摘要： Methods for treating pain are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with a narcotic analgesic or other pain relief agent.
摘要翻译： 公开了治疗疼痛的方法，其包括单独施用治疗有效量的胰岛淀粉样多肽或胰岛淀粉样多肽激动剂，或与麻醉性止痛剂或其它止痛剂联合施用。
-
公开(公告)号：US5656590A
公开(公告)日：1997-08-12
申请号：US157003
申请日：1993-11-24
申请人： Timothy J. Rink , Andrew A. Young
发明人： Timothy J. Rink , Andrew A. Young
摘要： Method for treatment of a patient suffering from anorexia or a related condition by administering amylin or an analogue thereof and/or to the patient in an amount sufficient to increase amylin and/or insulin levels in the plasma of the patient.
摘要翻译： PCT No.PCT / US92 / 04357 Sec。 371日期：1993年11月24日 102（e）日期1993年11月24日PCT提交1992年5月23日PCT公布。 WO92 / 20367 PCT出版物 日期1992年11月26日通过以足以增加患者血浆中的胰岛淀粉样多肽和/或胰岛素水平的量施用胰岛淀粉样多肽或其类似物和/或给予患者来治疗患有厌食症或相关病症的患者的方法。
-
59.发明授权Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions 失效用于治疗糖尿病，低血糖症和其他病症的方法和组合物
公开(公告)号：US5321008A
公开(公告)日：1994-06-14
申请号：US774411
申请日：1991-10-10
申请人： Kevin Beaumont , Andrew A. Young
发明人： Kevin Beaumont , Andrew A. Young
IPC分类号： A61K38/22 , A61K38/23 , A61K38/26 , A61K38/28 , A61K49/00 , A61P3/06 , A61K37/26 , A61K37/02
CPC分类号： A61K38/28 , A61K38/22 , A61K38/23 , A61K38/26 , A61K49/0008
摘要： Methods for treatment of diabetes and other insulin-requiring conditions by administering insulin and a calcitonin with or without amylin, and methods for treatment of hypoglycemic conditions by administering a calcitonin alone or in combination with glucagon and/or an amylin, and related compositions.
摘要翻译： 通过施用胰岛素和降钙素来治疗糖尿病和其它需要胰岛素的病症的方法，以及通过单独或与胰高血糖素和/或胰岛淀粉样多肽组合施用降钙素和相关组合物来治疗降血糖病症的方法。
-
公开(公告)号：US08895498B2
公开(公告)日：2014-11-25
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/00 , A61P3/10 , C07K7/06 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.046 秒)
